Eli Lilly on Tuesday said its recently approved weight loss treatment Zepbound is now available at pharmacies across the U.S., serving as an alternative to rival obesity drugs such as Wegovy that are facing supply issues.
High demand for the treatments has resulted in widespread shortages of Novo Nordisk 's Wegovy and diabetes drug Ozempic as well as Eli Lilly's diabetes treatment Mounjaro, pushing companies to ramp up production.
Eli Lilly also said in a release that its commercial savings card program, which aims to expand access to Zepbound, is now available to patients with a prescription.
Also on Tuesday, Eli Lilly said Zepbound was added to the preferred formulary, or list of covered drugs, of a major drug benefits company, Cigna .
Zepbound will be added to the commercial formularies of Cigna's health-care business on Dec. 15, according to Eli Lilly.
Eli Lilly, Eli, Zepbound, Rhonda Pacheco, Eli Lilly's
Novo Nordisk, CNBC PRO